The Clinical Algorithm Behind Menopause Treatment Decisions
When you sit in a doctor’s office asking for help with menopause symptoms, the decisions that follow are not random. Clinicians follow a menopause treatment algorithm — a structured decision tree that weighs symptom severity, your age and menopause timing, your medical history, and your personal preferences. The algorithm is not written on a whiteboard in the exam room, but it exists in the major clinical guidelines, and most knowledgeable providers use it implicitly. Understanding the algorithm helps you predict what your doctor will recommend — and push back if the recommendation does not fit.
The algorithm has three main decision points: whether symptoms are severe enough to need treatment, whether hormone therapy is safe for you, and which delivery method and dose to start with. Each step has explicit criteria that the menopause treatment guidelines from NAMS, NICE, and ACOG define. This article walks through each decision point with the specific rules and numbers that guide them.
Step 1: Is Symptom Severity High Enough for Pharmacologic Treatment?
The first branch in the menopause treatment algorithm divides women into three symptom categories. Mild symptoms — fewer than 4 hot flashes per day, no sleep disruption, no work or relationship interference — are managed with lifestyle measures alone. Moderate symptoms — 4 to 7 hot flashes per day, occasional night sweats, some sleep disturbance — start with lifestyle interventions and escalate if symptom control is inadequate. Severe symptoms — 8 or more hot flashes per day, regular night sweats, significant sleep and function impairment — warrant pharmacologic treatment from the outset.
This triage comes from the NAMS 2023 non-hormonal management position statement, which defines severe vasomotor symptoms as those that “clearly interfere with daily activities, work productivity, or quality of life.” The NICE 2024 guideline takes a simpler approach: treat based on the woman’s own assessment of symptom bother, not a rigid count. If the woman says her symptoms are severe enough to want medication, that is sufficient to trigger Step 2 of the algorithm.
The key practical point is that doctors who tell you “your symptoms are not bad enough for treatment” are departing from the algorithm. The NICE 2024 guideline explicitly states that “symptom severity should be determined by the patient.” If you are bothered enough to ask for treatment, the algorithm moves to Step 2.
Step 2: Is Hormone Therapy Safe for This Woman?
Once treatment is indicated, the algorithm asks a yes-or-no safety screening question. The contraindications to systemic hormone therapy are well-defined and consistent across all major guidelines: current or past breast cancer, known or suspected estrogen-dependent cancer, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active venous thromboembolism or history of VTE not on anticoagulation, active liver disease, and porphyria cutanea tarda.
If the woman has any of these contraindications, the algorithm branches to non-hormonal treatment options — Veozah, SSRIs/SNRIs, gabapentin, or pregabalin. If she has no contraindications, the algorithm proceeds to Step 3 with the note that benefits almost always outweigh risks for symptomatic women under 60 years old or within 10 years of menopause onset.
This risk-benefit calculation is anchored by the most recent data. The WHI follow-up published in 2024 tracked 27,347 women over 20 years. For women aged 50 to 59 starting hormone therapy, the excess risk of breast cancer was 2.6 additional cases per 10,000 women per year — compared to the general population background risk of 12.4 per 10,000 per year. The excess risk of stroke was 0.7 per 10,000 per year. For women with an intact uterus, the progestogen-containing regimens carried slightly higher risk than estrogen-alone — but both were well below 1 per 1,000 excess events per year for this age group.
Step 3: Which Hormone Therapy Delivery Method and Dose?
The third branch of the menopause treatment algorithm determines the route of administration. The first question is whether the woman has an intact uterus. If yes, she needs both estrogen and progestogen (or a SERM like bazedoxifene combined with estrogen in the Duavee product) to protect the endometrium. If she has had a hysterectomy, she can take estrogen alone — the simpler, lower-dose option.
Among women with a uterus, the algorithm offers a sub-branch. Sequential regimens (estrogen daily with progestogen for 12 to 14 days per month) are for women in perimenopause who still have periods. Continuous-combined regimens (both hormones daily) are for postmenopausal women who want to avoid any bleeding. The NAMS 2022 statement notes that continuous-combined regimens can cause breakthrough bleeding in the first six months, but 80% of women are amenorrheic by 12 months.
The preferred delivery method varies by risk profile. For women with obesity (BMI over 30), hypertension, migraine with aura, or a history of smoking, the algorithm recommends transdermal estrogen — patches, gel, or spray — over oral. The evidence for this recommendation comes from the ESTHER study, which found that oral estrogen increased VTE risk 4-fold compared to transdermal, while transdermal showed no significant increase. A 2025 meta-analysis in Thrombosis Research confirmed that transdermal estrogen has a VTE odds ratio of 0.9 (not statistically significant) compared to 1.4 for oral estrogen.
Starting doses are specified in the algorithm. For transdermal estradiol patches, the starting dose is 0.025 to 0.0375 mg/day. For oral estradiol, 0.5 mg/day. For conjugated equine estrogens, 0.3 mg/day. The rule is to start low and titrate up every four weeks based on symptom response. The HRT options guide includes a dose conversion table for switching between delivery methods.
Step 4: Is the Response Adequate?
After four to eight weeks on the starting dose, the algorithm requires a reassessment. If symptoms have improved by 75% or more — the NAMS-defined threshold for adequate response — the woman continues at the current dose with annual reevaluation. If symptoms have improved by 50% to 75%, the algorithm recommends increasing to the next dose level. If symptoms have improved by less than 50%, the algorithm asks two questions: is the woman using the treatment correctly (patch adhesion, consistent gel application), and is the delivery method appropriate?
The second question leads to a delivery method switch if needed. Some women absorb transdermal estradiol poorly due to skin characteristics — about 7% of women have low transdermal absorption according to a 2024 pharmacokinetic study. These women may need oral estrogen instead, or a higher patch dose. Similarly, women on oral estrogen who develop nausea or migraine may benefit from switching to transdermal. The algorithm allows for two method switches before declaring hormone therapy ineffective for a particular woman.
The KEEPS Continuation Study data, published in 2024, supports this stepwise approach. Women who required dose increases in the first six months had the same long-term satisfaction at five years as women who achieved control at the starting dose — suggesting that the dose-finding phase does not predict long-term success. Persistence through the adjustment period pays off.
Step 5: The Non-Hormonal Branch
For women who cannot or choose not to take hormones, the menopause treatment algorithm has a parallel branch. Veozah (fezolinetant 45 mg once daily) is the first-line non-hormonal option in the US, based on the SKYLIGHT 1 and 2 phase 3 trials published in The Lancet in 2023. For women who cannot access or afford Veozah, SSRIs and SNRIs are the next option: paroxetine 7.5 mg (the only FDA-approved SSRI for hot flashes), venlafaxine 37.5 to 75 mg, or escitalopram 10 to 20 mg.
Gabapentin (300 to 900 mg daily) is the third-line non-hormonal option in the algorithm, primarily for women who also have sleep disruption. The MsFLASH network found that gabapentin 900 mg daily reduced hot flash frequency by 46% compared to placebo — slightly less than Veozah’s 60% reduction but better than most SSRIs. Pregabalin is a fourth-line option reserved for women who fail other non-hormonal treatments.
The non-hormonal branch also includes cognitive behavioral therapy as a non-pharmacologic option that can be used alongside or instead of medication. The NICE 2024 algorithm places CBT at the same level as medication for women who prefer a non-drug approach. The non-hormonal treatment guide covers the full sequence with dosing and side effect profiles.
How the Algorithm Handles GSM Symptoms
Genitourinary syndrome of menopause has its own mini-algorithm within the broader framework. For women with GSM symptoms who are not on systemic hormone therapy, the algorithm starts with over-the-counter vaginal moisturizers (used every 2 to 3 days, not just during sex). If moisturizers are insufficient, the algorithm adds low-dose vaginal estrogen — cream, tablet, or ring — without the need for progestogen. For women who cannot use estrogen, vaginal dehydroepiandrosterone (Intrarosa, 6.5 mg daily) is the FDA-approved alternative.
The vaginal estrogen algorithm has no mandatory stop time. A 2025 consensus statement from the Menopause Society and the International Society for the Study of Women’s Sexual Health confirmed that vaginal estrogen can be continued indefinitely because systemic absorption is minimal. The only monitoring required is an annual pelvic exam. The estrogen therapy guide includes the full GSM treatment algorithm with visual decision trees.
The menopause treatment algorithm is a structured path, not a rigid set of rules. It guides decisions while allowing for individual variation. The most important thing to understand is that the algorithm starts with your reported symptoms — not with your age, not with your hormone levels, not with your doctor’s opinion about whether menopause “needs” treatment. If you know the algorithm, you can follow it together with your doctor and arrive at the right treatment faster.